Ultime notizie per Merchants Bancorp (NASDAQ:MBINM) Azioni

Merchants Bancorp is a United States based bank holding company. It operates multiple lines of business focusing on FHA (Federal Housing Administration) multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, traditional community banking. The business segments of the company are: Multi-family Mortgage Banking which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing segment which funds agency-eligible residential loans as well as commercial loans to nondepository financial institutions; and Banking segment that provides a wide range of financial products and services to consumers and businesses, including commercial and other consumer loan products.

FXDFR PRF PERPETUAL USD 25 - Ser D Dp sh 1/40th

Merchants Bancorp - Depositary Shares, Each Representing a 1/40th Interest in a Share of 8.25% Fixed-Rate Reset Series D Non-Cumulative Perpetual Preferred Stock

Merchants Bancorp

Lotus Technology Inc. ("Lotus" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOT#NASDAQ">LOT</a>), a leading global intelligent luxury mobility provider, announced that Lotus Robotics, a subsidiary of the Company, has to date achieved a total contract value1 of approximately US$130 million for its intelligent driving solutions, symbolizing a significant driver for the long-term and sustainable growth of the Company.
Lotus Robotics has secured agreements with leading global auto conglomerates across Europe, Japan and other key markets with over 40% of total contract value from Europe and Rest of the World, demonstrating the global market recognition of its self-owned technologies. Close to 10 different models to be delivered to global car owners are expected to be equipped with Lotus Robotics' driving solutions in the next 2-3 years.

News

Contracts

Lotus Technology's Lotus Robotics Has To Date Achieved A Total Contract Value Of ~$130M For Its Intelligent Driving Solutions, Symbolizing A Significant Driver For The Long-Term And Sustainable Growth Of The Company

Earnings

Walmart CEO Says East Coast Port Strikes And Storms Impacted Operating Income Growth Negatively In Q3; CFO Says US Consumers Remain Resilient And Are Largely Consistent In Behaviour Over The Past Four Or Six Quarters; CFO Says In Q3 Company Rolled Back Prices On 6,000 Items

Oppenheimer analyst Jeff Jones maintains Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) with a Outperform and lowers the price target from $14 to $12.

Price Target

Analyst Ratings

CLRB

Oppenheimer Maintains Outperform on Cellectar Biosciences, Lowers Price Target to $12

JP Morgan analyst Eric Joseph initiates coverage on Septerna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEPN#NASDAQ">SEPN</a>) with a Overweight rating and announces Price Target of $38.

Initiation

SEPN

JP Morgan Initiates Coverage On Septerna with Overweight Rating, Announces Price Target of $38

Benchmark analyst Mark Zgutowicz reiterates Criteo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>) with a Buy and maintains $51 price target.

Reiteration

CRTO

Benchmark Reiterates Buy on Criteo, Maintains $51 Price Target

Oppenheimer analyst Noah Kaye maintains Vertiv Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) with a Outperform and raises the price target from $121 to $131.

Oppenheimer Maintains Outperform on Vertiv Hldgs, Raises Price Target to $131

Spectral AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) ("Spectral AI" or the "Company"), an artificial intelligence (AI) company focused on revolutionizing medical diagnostics to enable faster, more accurate treatment decisions in wound care, today announced the successful completion of an approximate $5.0 million equity financing in an at-the-market transaction. The closing is to be completed in two tranches. Part of the proceeds will be used for the retirement of its outstanding obligations with Yorkville Advisors. This transaction supports Spectral AI's growth trajectory and progress toward a submission to the U.S. Food and Drug Administration ("FDA") for approval of its DeepView AI&#xAE;-Burn system, a crucial milestone targeted for the first half of 2025.
The equity financing was made possible through a strategic financing arrangement with institutional investors, a testament to Spectral AI's ability to attract significant financial support. This arrangement, which included an at-the-market offering of equity and pre-funded warrants, strengthens Spectral AI's balance sheet and enhances its operational flexibility as it pursues FDA approval.

Offerings

MDAI

Spectral AI Announces The Successful Completion Of An ~$5M Equity Financing In An At-The-Market Transaction, Strengthening Financial Position For FDA Pathway

Health Care

General

IRIX

Iridex Confirms That Local Coverage Determination L37531, Relating To Micro-Invasive Glaucoma Surgery Was Adopted As Scheduled And wll Be Effective For Services Performed After Nov. 17

Jefferies analyst Michael Prew initiates coverage on InvenTrust Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVT#NYSE">IVT</a>) with a Hold rating and announces Price Target of $33.

Jefferies Initiates Coverage On InvenTrust Properties with Hold Rating, Announces Price Target of $33

Highlights Include Solid Tumor Profiling, Liquid Biopsy Sensitivity, And HPV Subtyping Innovations

Biotech

NeoGenomics To Present Four Studies At AMP 2024 Showcasing ctDNA And NGS Advancements For Cancer Diagnostics And Personalized Treatment

Benchmark analyst Mark Palmer reiterates Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) with a Buy and maintains $16 price target.

BTDR

Benchmark Reiterates Buy on Bitdeer Technologies, Maintains $16 Price Target

NVNO

enVVeno Medical Submits PMA Application To FDA To Sell And Market VenoValve In The US

Loop Capital analyst Chris Dankert maintains Kennametal (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMT#NYSE">KMT</a>) with a Hold and raises the price target from $24 to $26.

Loop Capital Maintains Hold on Kennametal, Raises Price Target to $26

Vipshop Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIPS#NYSE">VIPS</a>) reported third-quarter sales of $2.95 billion,&nbsp;down by 9.2% year-on-year, which topped the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/n42056726/vipshop-reports-unaudited-third-quarter-2024-financial-results" rel="noreferrer noopener">Wall Street view of $2.91 billion</a>.
Vipshop Holdings&nbsp;registered&nbsp;adjusted earnings per ADS of 35 cents, which beat the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of 33 cents</a>.&nbsp;
Total orders for the quarter were 163.9 million,&nbsp;compared with 179.9 million in the prior year period.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42011906/exxon-mobil-set-to-cut-400-texas-jobs-after-pioneer-deal" rel="noreferrer noopener">Exxon Mobil To Cut 400 Texas Jobs In Stages Through 2026</a>
The number of active customers for the third quarter of 2024 was 39.6 million, down from 42.3 million a year ago.
Gross margin for the quarter increased to 24.0% from 23.6% in the prior year period. Gross profit declined 7.9%&nbsp;to&nbsp;4.96 billion Chinese Yuan&nbsp;($706.14 million).
GMV&nbsp;for the quarter was&nbsp;40.1 billion Chinese Yuan versus 42.5 billion Chinese Yuan a year ago.
As of&nbsp;September 30, 2024, the company had cash and cash equivalents, restricted&nbsp;cash&nbsp;of&nbsp;$3.2 billion, and&nbsp;short-term&nbsp;investments of&nbsp;$222.3 million.
During the quarter, the company repurchased&nbsp;$275.0 million&nbsp;of its ADSs under its current&nbsp;$1 billion&nbsp;share repurchase program,&nbsp;effective through&nbsp;March 2025.&nbsp;
Eric Shen, Chairman and CEO of Vipshop, highlighted the company's swift response to address external challenges and seize growth opportunities amidst soft industry trends in discretionary categories during the third quarter. He noted early positive outcomes from adjustments that improved the merchandising portfolio and operational efficiency while driving double-digit growth in active Super VIP customers. 
Despite the slow recovery in consumer spending, he emphasized a continued focus on long-term strategies and executing key retail fundamentals to support sustained growth.
Mark Wang, CFO of Vipshop, underscored the alignment of third-quarter results with expectations, driven by solid profitability through disciplined financial management. He detailed ongoing investments to enhance customer impact and growth while reallocating resources to create a more balanced business model. 
Additionally, he highlighted the company's commitment to shareholder value, with $275 million worth of shares repurchased during the quarter and plans for a new $1 billion repurchase program following the full utilization of the current one.
Outlook:&nbsp;For the fourth quarter of 2024, the company expects its total net revenues of&nbsp;31.2 billion Chinese Yuan &#8211; 32.9 billion Chinese Yuan, representing a <a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">year-over-year decrease of approximately 10% &#8211; 5%.&nbsp;</a>
Vipshop Holdings stock plunged over 20% year-to-date.
Price Action: VIPS stock is down 1.66% to $13.65 premarket at last check Tuesday.&nbsp;
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42006281/alibaba-q2-earnings-revenue-beats-forecast-cloud-and-international-sales-shine-free-cash-flow-falls-amid-strategic-investments" target="_blank" rel="noreferrer noopener">Alibaba Q2 Earnings: Revenue Beats Forecast, Cloud and International Sales Shine, Free Cash Flow Falls Amid Strategic Investments</a></li>
</ul>

Equities

Guidance

Movers

VIPS

Vipshop Beats Q3 Estimates Despite Sales Dip, Focuses On Long-Term Resilience

&nbsp;Select Medical Holdings Corporation ("Select Medical," "we," "us," or "our") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) today announced the distribution ratio for the previously announced special stock distribution (the "Distribution") to its stockholders of its equity interest in Concentra Group Holdings Parent, Inc. ("Concentra") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CON#NYSE">CON</a>). Based on the shares of Select Medical's common stock outstanding as of November 18, 2024, the record date (the "Record Date") for the Distribution, Select Medical's stockholders will receive 0.806971 shares of Concentra's common stock for every share of Select Medical's common stock held as of the close of business on the Record Date.
The Distribution by Select Medical of the special stock distribution will be made on November 25, 2024 (the "Distribution Date") in the form of a pro rata common stock distribution to all of Select Medical's stockholders of record on the Record Date. No fractional shares of Concentra's common stock will be distributed. Instead, Select Medical's stockholders will receive cash in lieu of any fraction of a share of Concentra's common stock that they otherwise would have received. The Distribution is generally intended to qualify as tax free to Select Medical's stockholders for U.S. federal income tax purposes.
J.P. Morgan and Goldman Sachs are acting as financial advisors to Select Medical in connection with the Distribution. Dechert LLP is acting as legal advisor to Select Medical in connection with the Distribution.

Dividends

Select Medical Holdings Corporation Announces Distribution Ratio For Special Stock Distribution To Stockholders; Stockholders Will Receive 0.806971 Shares Of Concentra's Common Stock For Every Share Of Select Medical's Common Stock Held As Of The Close Of Business On The Record Date

Fiscal 2025 Guidance
S&amp;W expects fiscal 2025 revenue to be within a range of $34.5 to $38 million. This includes approximately $4.1 million of international sales in the just completed first quarter of fiscal 2025. Adjusted EBITDA is expected to be in the range of ($5.0) million to ($3.0) million for fiscal 2025. Adjusted EBITDA for the first quarter of fiscal 2025 was ($3.1) million indicating that the Company expects adjusted EBITDA for the remaining three quarters of the fiscal year to be in a range of ($1.9) to $0.1 million.

SANW

S&W Seed 2025 Guidance: Expects Revenue Of $34.5M-$38M; Sees Adjusted EBITDA Of ($5.0)M-($3.0)M

Northern Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTIC#NASDAQ">NTIC</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.19 by 5.26 percent. This is a 566.67 percent increase over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $23.35 million which beat the analyst consensus estimate of $22.50 million by 3.77 percent. This is a 12.74 percent increase over sales of $20.71 million the same period last year.

Earnings Beats

NTIC

Northern Technologies Q4 Adj $0.20 Beats $0.19 Estimate, Sales $23.35M Beat $22.50M Estimate

Buybacks

CTVA

Corteva Agriscience Announces $3B Share Repurchase Program

Jefferies analyst Roger Song upgrades Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Hold to Buy and raises the price target from $2 to $7.

Upgrades

ACRS

Jefferies Upgrades Aclaris Therapeutics to Buy, Raises Price Target to $7

Akari Therapeutics, Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKTX#NASDAQ">AKTX</a>) announces receipt of written notice from the Listing Qualifications Staff of The Nasdaq Stock Market LLC informing the Company that its deficiency under Listing Rule 5550(b) has been cured. The Company is now in full compliance with all Nasdaq continued listing requirements.
Based on the foregoing, the previously scheduled Nasdaq hearing before the Hearings Panel on November 21, has been cancelled. The Company will continue to be traded on The Nasdaq Capital Market.

AKTX

Akari Therapeutics Regains Full Nasdaq Compliance, Shareholders Equity Deficiency Has Been Cured

Merchants Bancorp 8.25% DEP SHS REPSTG 1/40TH PERP PFD goes ex dividend tomorrow

Moon Capital Management Q4 2023 Letter

Moon Capital - Merchants Bancorp: The Bank You've Never Heard Of

Merchants Bancorp 8.25% DEP SHS REPSTG 1/40TH PERP PFD declares $0.5156 dividend

39 Upcoming Dividend Increases Including 2 Dividend Kings

Merchants Bancorp And Preferreds Reviewed

Merchants Bancorp 8.25% DEP SHS REPSTG 1/40TH PERP PFD goes ex-dividend tomorrow

Merchants Bancorp: A Shift To The Floating Preferred

ALLE

ALLY

ARES

BAMGF

BAMKF

BCEFF

BCEIF

BCEPF

BCEXF

BCPPF

BECEF

BKAMF

BKFAF

BKFPF

BROXF

BXDIF

CCOI

CSGS

CTRA

DJIA

ESNT

FAXRF

FAXXF

FFHPF

FRFFF

FRFGF

FRFHF

FRFXF

FRFZF

FXFHF

FXFLF

GFIOF

GILD

GLPI

GRBK

KFRC

LMAT

MBIN

MBINM

MBINN

MBINO

MBINP

OLED

PLDGP

SBAC

SCHD

SFNC

SLGN

TROW

UNTY

VRSK

Press Releases

Merchants Bancorp Increases Quarterly Common Dividend by 13%; Declares Quarterly Common and Preferred Dividends

Merchants Bancorp Declares Quarterly Common and Preferred Dividends

Enact Holdings

Federal Agricultural Mortgage Corporation Common Stock

Federal Agricultural

Better Home & Finance

CNFinance Holdings Limited American Depositary Shares, each representing twenty (20) Ordinary Shares

CNFinance Hldgs

Mr. Cooper Gr

Essent Group

Finance of America Companies Inc. Class A Common Stock

Finance of America

Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests

Comments

Merchants Bancorp

Notizie

Ultime notizie per Merchants Bancorp (NASDAQ:MBINM) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO